Office of Management and Budget
Executive Summary
OMB's announced re-review of pending rules is expected to have little impact on FDA because the agency has eliminated much of its regulatory backlog and any current delays are at the FDA level. OMB Director Leon Panetta has directed agencies not to send any rules to the Federal Register for publication unless approved by "an agency head" who is "appointed by President Clinton and confirmed by the Senate." FDA has sent a list of about 30 minor regulations that are ready for publication.